Sign for Notice Everyday    Sign Up| Sign In| Link|

Our Sponsors

    Receive Latest News

    Share Us

    ESLD14 2023 - End Stage Liver Disease Training Program and Treatment Update 2014

    View: 4142

    Website | Edit Freely

    Category Gastroenterolgy

    Deadline: August 14, 2018 | Date: August 14, 2023

    Venue/Country: San Diego, U.S.A

    Updated: 2014-06-21 08:12:24 (GMT+9)

    Call For Papers - CFP

    The number of patients with ESLD in the US is expected to continue to grow through 2020, largely due to the burden of chronic viral hepatitis and fatty liver disease which already exists in our population. As they age, a larger number of patients will develop decompensation events such as bleeding from esophageal varices, hepatic encephalopathy, hepatocellular carcinoma, ascites, hyponatremia and renal failure. The expected increase in number of ESLD patients will create more demand for health care providers who are able to care for the growing population, both in and out of the hospital. As such, this cutting edge, three quarter day course will teach diagnosis and management of common complications seen in patients with ESLD. After attending this educational program, the attendee will be able to recognize the treatable complications quickly and use the latest therapies in a reasonable fashion. Learning will concentrate on the areas which are evidence-based or literature-based; including portosystemic encephalopathy, ascites, hyponatremia, hepatocellular carcinoma screening and treatment, hepatorenal syndrome and bleeding due to portal hypertension.

    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.